MAPK3 and neoplasm: Cell viability assays demonstrated that compound 29 showed superior anti-proliferative activities over compound 30 in three tumor-derived cell lines (A375, D54, and SET-2), owing to 29 being able to inhibit downstream AKT and ERK1/2 phosphorylation.